Eleni Koufoglou1, Georgia Kourlaba1, Athanasios Michos2. 1. Department of Paediatric Infectious Diseases, First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Thivon and Papadiamantopoulou, 11527, Athens, Greece. 2. Department of Paediatric Infectious Diseases, First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Thivon and Papadiamantopoulou, 11527, Athens, Greece. amichos@med.uoa.gr.
Abstract
BACKGROUND: Prophylactic administration of antipyretics at the time of immunization seems to decrease some side effects, however reduced immune responses have been reported in some studies. This systematic review aimed to investigate the effect of prophylactic use of antipyretics on the immune response following administration of pneumococcal conjugate vaccines (PCVs). METHODS: A systematic review of randomized controlled trials and observational studies concerning the immune response to PCVs after antipyretic administration was performed up to November 2020 in the electronic databases of Pubmed and Scopus. RESULTS: Of the 3956 citations retrieved, a total of 5 randomized control trials including 2775 children were included in the review. Included studies were referred to PCV10 (3 studies), PCV7 and PCV13 (one study each). The prophylactic administration of paracetamol decreased the immune response to certain pneumococcal serotypes in all included studies. The effect was more evident following primary vaccination and with immediate administration of paracetamol. Despite the reductions in antibody geometric mean concentrations, a robust memory response was observed following the booster dose. Besides, antibody titers remained above protective levels in 88-100% of participants. The use of ibuprofen, that was evaluated in two studies, did not seem to affect the immunogenicity of PCVs . CONCLUSION: Although the reviewed studies had significant heterogeneity in design, paracetamol administration seems to affect the immune response for certain serotypes. The clinical significance of reduced immunogenicity especially before booster dose needs further investigation.
BACKGROUND: Prophylactic administration of antipyretics at the time of immunization seems to decrease some side effects, however reduced immune responses have been reported in some studies. This systematic review aimed to investigate the effect of prophylactic use of antipyretics on the immune response following administration of pneumococcal conjugate vaccines (PCVs). METHODS: A systematic review of randomized controlled trials and observational studies concerning the immune response to PCVs after antipyretic administration was performed up to November 2020 in the electronic databases of Pubmed and Scopus. RESULTS: Of the 3956 citations retrieved, a total of 5 randomized control trials including 2775 children were included in the review. Included studies were referred to PCV10 (3 studies), PCV7 and PCV13 (one study each). The prophylactic administration of paracetamol decreased the immune response to certain pneumococcal serotypes in all included studies. The effect was more evident following primary vaccination and with immediate administration of paracetamol. Despite the reductions in antibody geometric mean concentrations, a robust memory response was observed following the booster dose. Besides, antibody titers remained above protective levels in 88-100% of participants. The use of ibuprofen, that was evaluated in two studies, did not seem to affect the immunogenicity of PCVs . CONCLUSION: Although the reviewed studies had significant heterogeneity in design, paracetamol administration seems to affect the immune response for certain serotypes. The clinical significance of reduced immunogenicity especially before booster dose needs further investigation.
Entities:
Keywords:
Analgesics; And immune response; Antipyretics; Conjugate; Immunogenicity; Pneumococcal vaccine
Authors: Caroline L Trotter; Jodie McVernon; Mary E Ramsay; Cynthia G Whitney; E Kim Mulholland; David Goldblatt; Joachim Hombach; Marie-Paule Kieny Journal: Vaccine Date: 2008-06-17 Impact factor: 3.641
Authors: Ajoke Sobanjo-ter Meulen; Timo Vesikari; Edgardo A Malacaman; Steven A Shapiro; Michael J Dallas; Patricia A Hoover; Richard McFetridge; Jon E Stek; Rocio D Marchese; Jonathan Hartzel; Wendy J Watson; Luwy K Musey Journal: Pediatr Infect Dis J Date: 2015-02 Impact factor: 2.129
Authors: Nick J Andrews; Pauline A Waight; Polly Burbidge; Emma Pearce; Lucy Roalfe; Marta Zancolli; Mary Slack; Shamez N Ladhani; Elizabeth Miller; David Goldblatt Journal: Lancet Infect Dis Date: 2014-07-17 Impact factor: 25.071
Authors: Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney Journal: Lancet Infect Dis Date: 2015-02-03 Impact factor: 25.071
Authors: Lone Simonsen; Robert J Taylor; Cynthia Schuck-Paim; Roger Lustig; Michael Haber; Keith P Klugman Journal: Lancet Respir Med Date: 2014-03-10 Impact factor: 30.700
Authors: Wallis C Y Lau; Macey Murray; Aisha El-Turki; Sonia Saxena; Shamez Ladhani; Paul Long; Mike Sharland; Ian C K Wong; Yingfen Hsia Journal: Vaccine Date: 2015-08-19 Impact factor: 3.641
Authors: Brian Wahl; Katherine L O'Brien; Adena Greenbaum; Anwesha Majumder; Li Liu; Yue Chu; Ivana Lukšić; Harish Nair; David A McAllister; Harry Campbell; Igor Rudan; Robert Black; Maria Deloria Knoll Journal: Lancet Glob Health Date: 2018-07 Impact factor: 26.763
Authors: Eng Eong Ooi; Arti Dhar; Richard Petruschke; Camille Locht; Philippe Buchy; Jenny Guek Hong Low Journal: NPJ Vaccines Date: 2022-03-02 Impact factor: 9.399